Merus N.V. is a biotechnology company that specializes in the development of innovative therapeutic solutions, particularly focused on creating bispecific antibodies for cancer treatment. By leveraging its proprietary technology platforms, Merus aims to enhance the effectiveness of cancer therapies by targeting multiple pathways simultaneously, ultimately improving patient outcomes. The company's research and development efforts are directed towards various oncology indications, with a commitment to advancing clinical trials and bringing new treatments to market that can address unmet medical needs in the fight against cancer. Read More
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44. The company's market cap stands at $156.6 million.
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday. Shares of Tilray Brands, Inc. (NASDAQ: TLRY) rose sharply during Monday's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
In the preceding three months, 4 analysts have released ratings for Merus (NASDAQ: MRUS), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Merus N.V. (NASDAQ: MRUS) to Genmab A/S for $97.00 per share is fair to Merus shareholders.
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3 development, for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion. The transaction has been unanimously approved by the Boards of Directors of both companies. A wholly owned subsidiary of Genmab (“Purchaser”) will commence a tender offer for 100% of Merus’ common shares, which is anticipated to close by early in the first quarter of 2026.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET.
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2016 Incentive Award Plan (the “Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 240,000 shares of its common stock to two new employees. The stock options were granted on August 1, 2025. The grant was approved by the Board of Directors and a majority of independent directors based on the recommendation of the Compensation Committee and made as a material inducement to such employees entering into employment with Merus in accordance with Nasdaq Listing Rule 5635(c)(4). The option awards have an exercise price of $ 65.56 per share, the closing price of Merus’ common stock on August 1, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and the standard forms of grant agreements thereunder.
MERUS NV (NASDAQ:MRUS) shows strong technicals with a 7/10 rating and a high-quality 9/10 setup, suggesting a potential breakout above $56.23. Support at $52.32-53.52 provides a clear risk level.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters’ option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the launch of a proposed underwritten public offering of its common shares (the “Offer Shares”). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences:
